Categories: NewsPharmaceutical

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 109 new employees, in each case with a grant date of January 16, 2024, as equity inducement awards under the terms of the company’s 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as inducement material to the employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 14,206 shares of Madrigal’s common stock, and in the aggregate 32,788 time-based restricted stock units. All options granted have an exercise price of $243.92 per share, and vest as follows (i) 25% of the option shares will vest on the first anniversary of the date of grant and (ii) 6.25% of the option shares shall vest on each quarterly anniversary following the first anniversary of the date of grant. All restricted stock units granted vest in a 25% increment on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a liver-directed THR-β agonist oral therapy that is designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Staff

Recent Posts

Dr. Todd H. Lanman Presented Alignment-Driven Synergy Disc(R) Results and Case Experience at the 2nd Annual Hoag Orthopedic Institute Spine Symposium

Synergy Disc® presentation showcased statistically superior IDE trial outcomes, restoration of cervical lordosis, and long-term…

54 minutes ago

From Fusion to Motion: Dr. Joel S. Beckett Presented Restorative Motion Surgery Concepts at the Hoag Orthopedic Institute Spine Symposium

Presentation explored motion-restoring alternatives for select patients with persistent pain or pseudoarthrosis following cervical fusion…

54 minutes ago

IAVI to Advance Vaccine Candidate for Bundibugyo Virus, Receives Funding from CEPI

WHO identifies rVSV-based candidate as a top priority amid growing Ebola epidemic with no approved…

54 minutes ago

Medical Care Technologies (OTC PINK:MDCE) Provides Initial Overview of Melanoma Scan Beta User Experience and Interface Design

Company highlights streamlined body-map tracking and image management features designed to support long-term skin monitoring…

55 minutes ago

Edison Issues Report on Nabaltec (NTG)

London, United Kingdom--(Newsfile Corp. - June 1, 2026) - Edison issues report on Nabaltec (XETRA:…

2 hours ago

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB)…

4 hours ago